MORRIS PLAINS, N.J., June 3 /PRNewswire-FirstCall/ -- Immunomedics, Inc.
(Nasdaq: IMMU) today announced that 7 presentations are scheduled at the ASCO
meeting in New Orleans from June 5-8, 2004. These include the following:
Abstract 6579 -- Leukemia, Lymphoma and Transplantation Session, Sunday,
June 6, 2004, 8:00 am - 12:00 pm. Multi-centre, phase II study of combination
antibody therapy with epratuzumab plus rituximab in relapsed/refractory
indolent and aggressive NHL: Promising clinical results.
Abstract 6580 -- Leukemia, Lymphoma and Transplantation Session, Sunday,
June 6, 2004, 8:00 am - 12:00 pm. Initial results of a pilot study of
epratuzumab and rituximab in combination with CHOP chemotherapy (ER-CHOP) in
previously untreated patients with diffuse large B-cell lymphoma (DLBCL).
Abstract 6535 -- Leukemia, Lymphoma and Transplantation Session, Sunday,
June 6, 2004, 1:00 pm - 5:00 pm. Therapeutic activity of a new antibody-drug
immunoconjugate, IMMU-110, in preclinical studies targeted against multiple
myeloma.
Abstract 2545 -- Developmental Therapeutics: Immunotherapy Session,
Monday, June 7, 2004, 8:00 am - 12:00 pm. Radioimmunotherapy in non-Hodgkin's
lymphoma (NHL) using a fractionated schedule of DOTA-conjugated, 90Y-
radiolabeled, humanized anti-CD22 monoclonal antibody, epratuzumab.
Abstract 2555 -- Developmental Therapeutics: Immunotherapy Session,
Monday, June 7, 2004, 8:00 am - 12:00 pm. Therapeutic effects of anti-CEA
(CEACAM5) and anti-NCA90 (CEACAM6) antibody monovalent fragments in vitro and
in vivo.
Abstract 3155 -- CEA radioimmunotherapy of post-salvage resected
colorectal cancer liver metastases is safe and potentially effective in
extending survival. Accepted for publication in 2004 Annual Meeting
Proceedings America Society of Clinical Oncology. Vol. 23. Page 233.
Abstract 3105 -- Recombinant bispecific antibodies (bsMAb) to
carcinoembryonic antigen (CEA): Promising new agents for pretargeted
radioimmunotherapy (RAIT) of solid tumors. Accepted for publication in 2004
Annual Meeting Proceedings America Society of Clinical Oncology. Vol. 23. Page
221.
Immunomedics is a biopharmaceutical company focused on the development,
manufacture and commercialization of diagnostic imaging and therapeutic
products for the detection and treatment of cancer and other serious diseases.
Integral to these products are highly specific monoclonal antibodies and
antibody fragments designed to deliver radioisotopes and chemotherapeutic
agents to tumors and other sites of disease. Immunomedics has nine
therapeutic product candidates in clinical development and has two marketed
diagnostic imaging products. The most advanced therapeutic product candidates
are LymphoCide(R) (epratuzumab), for which certain Phase II clinical trials
for the treatment of non-Hodgkin's lymphoma have already been completed, and
CEA-Cide(R) (labetuzumab), which is in Phase I/II clinical trials for the
treatment of certain solid tumors.
This release, in addition to historical information, contains forward-
looking statements made pursuant to the Private Securities Litigation Reform
Act of 1995. Such statements, including statements regarding clinical trials,
involve significant risks and uncertainties and actual results could differ
materially from those expressed or implied herein. Factors that could cause
such differences include, but are not limited to, risks associated with new
product development (including clinical trials outcome and regulatory
requirements/actions), competitive risks to marketed products and availability
of financing and other sources of capital, as well as the risks discussed in
the Company's Annual Report on Form 10-K for the year June 30, 2003. The
Company is not under any obligation, and the Company expressly disclaims any
obligation, to update or alter any forward-looking statements, whether as a
result of new information, future events or otherwise.
Company Contact: Trish Merwin, Finance & Investor Relations Coordinator,
(973) 605-8200, extension 263. Visit the Company's web site at
http://www.Immunomedics.com.
SOURCE Immunomedics, Inc.
 back to top
Related links:
http://www.Immunomedics.com
Company News On-Call:
http://www.prnewswire.com/comp/113121.html
CONTACT:
Trish Merwin, Finance & Investor Relations
Coordinator of Immunomedics, Inc. +1-973-605-8200, extension 263
|
